Literature DB >> 25117197

Daclatasvir + asunaprevir: first global approval.

Raewyn M Poole1.   

Abstract

The combination of daclatasvir + asunaprevir [Daklinza(®) + Sunvepra(®) (Japan)], two direct-acting antiviral agents, has been developed by Bristol-Myers Squibb for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infections, including those with compensated cirrhosis. Daclatasvir + asunaprevir has received its first global approval in this indication in Japan. Daclatasvir + asunaprevir is the first all-oral, interferon- and ribavirin-free regimen for this indication. This article summarizes the milestones in the development of daclatasvir + asunaprevir leading to this first approval for the treatment of chronic HCV genotype 1 infections.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25117197     DOI： 10.1007/s40265-014-0279-4

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  32 in total

Review 1.  Treatment of chronic hepatitis C--are interferons really necessary?

Authors:  Peter Ferenci
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

2.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

3.  Management of recurrent hepatitis C following liver transplantation.

Authors:  Stevan A Gonzalez
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-10

4.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

5.  An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2011-09-26       Impact factor: 17.425

6.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors:  Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

Review 7.  Perspectives and challenges of interferon-free therapy for chronic hepatitis C.

Authors:  Christian M Lange; Stefan Zeuzem
Journal:  J Hepatol       Date:  2012-10-24       Impact factor: 25.083

8.  Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.

Authors:  Yoshiyasu Karino; Joji Toyota; Kenji Ikeda; Fumitaka Suzuki; Kazuaki Chayama; Yoshiiku Kawakami; Hiroki Ishikawa; Hideaki Watanabe; Dennis Hernandez; Fei Yu; Fiona McPhee; Hiromitsu Kumada
Journal:  J Hepatol       Date:  2012-11-22       Impact factor: 25.083

Review 9.  Current prospects for interferon-free treatment of hepatitis C in 2012.

Authors:  Catherine A M Stedman
Journal:  J Gastroenterol Hepatol       Date:  2013-01       Impact factor: 4.029

Review 10.  Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives.

Authors:  Hee Bok Chae; Seon Mee Park; Sei Jin Youn
Journal:  ScientificWorldJournal       Date:  2013-06-05
View more
  14 in total

1.  Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.

Authors:  Aurélie Barrail-Tran; Corine Vincent; Valérie Furlan; Isabelle Rosa; Eric Rosenthal; Antoine Cheret; Jean-Michel Molina; Anne-Marie Taburet; Lionel Piroth
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

2.  Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir.

Authors:  Jun Matsumoto; Su Nwe San; Masachika Fujiyoshi; Ayano Kawauchi; Natsumi Chiba; Ran Tagai; Ryoko Sanbe; Shiho Yanaka; Hiroaki Sakaue; Yoshinori Kato; Hiroyoshi Nakamura; Harumi Yamada; Noritaka Ariyoshi
Journal:  J Hum Genet       Date:  2019-10-23       Impact factor: 3.172

Review 3.  A 2015 roadmap for the management of hepatitis C virus infections in Asia.

Authors:  Seng Gee Lim; Yock Young Dan
Journal:  Korean J Intern Med       Date:  2015-06-29       Impact factor: 2.884

4.  Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.

Authors:  Yugo Kai; Hayato Hikita; Tomohide Tatsumi; Tasuku Nakabori; Yoshinobu Saito; Naoki Morishita; Satoshi Tanaka; Takatoshi Nawa; Tsugiko Oze; Ryotaro Sakamori; Takayuki Yakushijin; Naoki Hiramatsu; Hiroshi Suemizu; Tetsuo Takehara
Journal:  J Gastroenterol       Date:  2015-07-25       Impact factor: 7.527

Review 5.  Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.

Authors:  Heidi Barth
Journal:  World J Hepatol       Date:  2015-04-18

6.  Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor.

Authors:  Barbara Zheng; Stanley V D'Andrea; Li-Qiang Sun; Alan Xiangdong Wang; Yan Chen; Peter Hrnciar; Jacques Friborg; Paul Falk; Dennis Hernandez; Fei Yu; Amy K Sheaffer; Jay O Knipe; Kathy Mosure; Ramkumar Rajamani; Andrew C Good; Kevin Kish; Jeffrey Tredup; Herbert E Klei; Manjula Paruchuri; Alicia Ng; Qi Gao; Richard A Rampulla; Arvind Mathur; Nicholas A Meanwell; Fiona McPhee; Paul M Scola
Journal:  ACS Med Chem Lett       Date:  2018-01-19       Impact factor: 4.345

Review 7.  HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.

Authors:  Kazuaki Chayama; C Nelson Hayes
Journal:  Viruses       Date:  2015-10-13       Impact factor: 5.048

8.  Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report.

Authors:  Leon Louis Seifert; Hauke Heinzow; Iyad Kabar; Stefan Christensen; Anna Hüsing; Hartmut H-J Schmidt
Journal:  Am J Case Rep       Date:  2016-08-24

Review 9.  Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection.

Authors:  Alireza FakhriRavari; Mazyar Malakouti; Rebecca Brady
Journal:  J Clin Transl Hepatol       Date:  2016-06-15

10.  Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.

Authors:  Fumitaka Suzuki; Naoya Hatanaka; Etsuya Bando; Koji Nakamura; Akira Komoto
Journal:  Hepatol Int       Date:  2018-06-09       Impact factor: 9.029
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.